Cancer Breakthrough Fund

Investing Today Transforming Tomorrow

Launched with founding partner the Terry Fox Foundation, the Cancer Breakthrough Fund has since expanded to include the Canadian Cancer Society, impact funds, mission-driven foundations, institutional investors, and family offices. By combining venture capital expertise with the scientific and clinical networks of two of Canada’s leading philanthropic entities, the Fund is uniquely positioned to support the development of new therapies that improve patient outcomes.

10 Million Annual Cancer Deaths

~77%
Increase in cancer incidence by 2050, rising from ~ 20 million cases in 2022
~1/3
Of all new U.S. drug approvals are for cancer, reflecting its central role in biopharma innovation
~30%
Of biotech venture capital funding flows into oncology, making cancer the largest focus area in life sciences
<50%
5-year survival rates across multiple cancers, underscoring the unmet need in cancer treatment

Despite Innovation The Problem Persists

“The Fund was built on the belief that uniting philanthropic mission with venture capital expertise to support cancer innovation would offer the potential to unlock transformative outcomes for patients, and today’s milestone highlights the tremendous power of this model.”

– Peter van der Velden,
Executive Chairman, Lumira Ventures

Cancer Breakthrough Fund News

Our CanadianPhilanthropic Partners

TFF_RGB_Vertical_TerryBlue
CCS_Logo_2022_RGB_EN_2C

OurPartners and Funders

realize-capital-partners
BOANN_Logo_bilingual
Northpine_Logo_RGB_220302
and Family Offices
Scroll to Top